Mode
Text Size
Log in / Sign up
N/A N=38 Randomized Single-blind Prevention

Improving HIV Outcomes Among African American Transgender Women

HIV

Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Oct 2023
Primary outcome: Primary: Change in Percentage of Participants With HIV Transmission Risk at Month 6 — 23.077; 38.462; 46.154; 46.154 percentage of participants with no risk — p=.19

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Shine (Behavioral); Control (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
Male
Sponsor
ISA Associates, Inc.
Primary completion
Jan 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Percentage of Participants With HIV Transmission Risk at Month 6
23.077; 38.462; 46.154; 46.154 .19
SECONDARY
Change in ART Adherence at Month 6
3.38; 5.25; 6.50; 6.50 =.24
SECONDARY
Change in Condom Use at Month 6
51.79; 49.39; 37.33; 58.84 .79
SECONDARY
Change in Barriers to ART Use at Month 6
1.02; 1.04; .70; .86 .81
SECONDARY
Change in Barriers to PrEP Use at Month 6
2.62; 2.02; 2.18; 2.13 .14
SECONDARY
Change in Barriers to Condom Use at Month 6
1.20; 1.09; 1.05; .76 .81
SECONDARY
Change in Social Support at Month 6
2.57; 2.68; 2.86; 2.53 .30
SECONDARY
Change in Gender Identity Comfort at Month 6
3.13; 3.12; 3.17; 3.13 .94

Summary

The investigators will conduct a randomized controlled trial to test the efficacy of the mobile HIV behavioral intervention for African American transgender women (Shine). Participants will be 215 trans women recruited by staff of the Trans Women of Color Collective via community events and social media. Participants must : 1) identify as a Black transgender woman using the 2-step method (Step 1: assigned male birth sex, Step 2: current gender identity is female); 2) be aged 18 or older; 3) report risk of HIV transmission in past 3 months (i.e., CAS with a serodiscordant or risky partner AND either <90% ART adherence or <5 daily doses of PrEP per week); 4) own a smartphone; and 5) be able to read and speak English. Eligible participants who subsequently provide informed consent will complete two confidential phone-based research surveys at different time points (baseline and 6 months post-baseline) and will be randomly assigned to one of two conditions (Shine or mobile HIV education for transgender women). Participants randomly assigned to the experimental condition will be instructed to text the word "Join" to the Shine study phone number. The intervention will take approximately 1-2 hours, with content delivered over several weeks. Participants randomly assigned to the control condition will be texted a link to a set of videos on healthy HIV-related behaviors for transgender women. These videos cover a variety of topics, including recommended testing frequencies, PrEP, and ART. After randomization, participants will complete the baseline research survey. This survey will assess the primary outcome of composite HIV transmission risk along with several secondary outcomes (individual behavioral components of the composite score; HIV medical care utilization and adherence; HIV testing; PrEP knowledge, interest, and uptake; gender affirmation; well-being; social support; sexual communication). Six months after the baseline research survey, all participants will complete a follow-up research survey assessing the same outcome measures in the baseline research survey. Binomial logistic regression will be the main analytic technique for the primary measure (composite risk for HIV transmission). For the secondary continuous measures, hierarchical linear modeling (HLM) will be used. All models will control for any demographic covariate (e.g., age) that varies at the .2 significance level due to randomization failure at baseline.

Eligibility Criteria

Inclusion Criteria

  • African American/Black
  • identifies as a transgender woman using the recommended 2-step method (Step 1: assigned male birth sex, Step 2: current gender identity is female)
  • 18 or older
  • report risk of HIV transmission in past 3 months (i.e., CAS with a serodiscordant or risky partner AND either <90% ART adherence or <5 daily doses of PrEP per week)
  • owns a mobile phone capable of SMS messaging and accessing webpages
  • able to speak/understand English

Exclusion Criteria

  • does not meet inclusion criteria
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05483686). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search